AKR1C2 acts as a targetable oncogene in esophageal squamous cell carcinoma via activating PI3K/AKT signaling pathway.

Journal of Cellular and Molecular Medicine
Zhan-Fei ZhangBi-Jun Huang

Abstract

The aldo-keto reductases family 1 member C2 (AKR1C2) has critical roles in the tumorigenesis and progression of malignant tumours. However, it was also discovered to have ambiguous functions in multiple cancers and till present, its clinical significance and molecular mechanism in oesophageal squamous cell carcinoma (ESCC) has been unclear. The aim of this study was to explore the role of AKR1C2 in the tumorigenesis of ESCC. Here, we showed that AKR1C2 expression was found to be up-regulated in ESCC tissues and was significantly associated with pathological stage, lymph node metastasis and worse outcomes. Functional assays demonstrated that an ectopic expression of AKR1C2 in ESCC cells resulted in increased proliferation, migration and cisplatin resistance, while knockdown led to inversing effects. Bioinformation analyses and mechanistic studies demonstrated that AKR1C2 activated the PI3K/AKT signalling pathway, furthermore, the inhibitor of PI3K or the selective inhibitor of AKR1C2 enzyme activity could reverse the aggressiveness and showed synergistic antitumour effect when combined with cisplatin, both in vitro and in vivo. In conclusion, Our findings revealed that AKR1C2 could function as an oncogene by activating the PI3K/...Continue Reading

References

Jun 16, 2004·International Journal of Cancer. Journal International Du Cancer·Liang-Shun WangWing-Yin Li
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Barbara BurtnessUNKNOWN Eastern Cooperative Oncology Group
Jan 19, 2006·Journal of the American Chemical Society·Yong XuGlenn D Prestwich
Apr 28, 2006·Journal of Neurochemistry·Olga A AgapovaM Rosario Hernandez
Apr 7, 2011·Cancer Biology & Therapy·Hongxia LiShih Hsin Lu
Nov 6, 2013·Steroids·Tea Lanišnik Rižner, Trevor M Penning
Dec 3, 2014·Chemico-biological Interactions·Maša SinreihTea Lanišnik Rižner
Sep 1, 2015·Journal of Biomolecular Screening·Cong LiJiasheng Zheng
Sep 10, 2015·Oncology Research·Cong LiJiasheng Zheng
Nov 18, 2015·International Journal of Clinical Oncology·Antonia WennersMaret Bauer
Jan 26, 2016·CA: a Cancer Journal for Clinicians·Wanqing ChenJie He
Feb 11, 2016·Biochemical Society Transactions·Matthew J Eramo, Christina A Mitchell
Oct 28, 2016·Annals of the New York Academy of Sciences·Yongjing LiuXiaoxin Luke Chen
Mar 9, 2018·British Journal of Cancer·Roberta BortolozziLuca Persano
Dec 16, 2018·Best Practice & Research. Clinical Gastroenterology·Tom van den EndeHanneke W M van Laarhoven
Dec 21, 2018·Medicinal Research Reviews·Dan LiTingjun Hou
Apr 20, 2019·Seminars in Cancer Biology·Samanta SalviSara Bravaccini
May 12, 2019·Pharmacology & Therapeutics·Clasina M VenemaElisabeth G E de Vries
Jul 12, 2019·Journal of Cancer·Yi-Xiang JinEn-Dong Chen

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
xenografts
xenograft
flow cytometry

Software Mentioned

GraphPad Prism
SPSS

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.